

contd.
a¹

delivered to the lungs by inhalation. It is desirable that the substance is long acting and non-irritant.--

Please **amend** page 2, lines 14-18, of the specification, as follows: ✓

a²

--As described by De Souza *et al.* and in GB-A-1597717, trequinsin has valuable pharmacological properties, and can be administered to human subjects suffering from, for example, respiratory disorders. However, it is unsuitable for administration by inhalation because *in vitro* data indicate its persistence of action is less than desirable.--

Please **amend** page 2, lines 20-22 of the specification, as follows: ✓

a³

--It has now been found that it is possible to design certain pyrimido [6,1-A] isoquinolin-4-one derivatives which are PDE inhibitors, which have a longer duration of action relative to trequinsin.--

On page 46, please **delete** lines 4-22. ✓

At the **last** page of the specification, please **insert** the **attached abstract**. ✓

IN THE CLAIMS

Please cancel claims 26, 37, 42, 46, 49, and 50.

Please amend claim 47 as follows:

a³

47. (Amended) A method as claimed in any one of claims 44 to 45, wherein the compound is administered by aerosol.